November 7, 2025
Buy dips as sector earnings surpassed, met, beat or missed expectations with whipsaw depreciations actions ensuing as the stock market headed south; with “blood on the street” time to “dip one’s toes” into the C> sector
Counting: 7 negatives and 2 positive closes out of 9 sessions – We’re Due!
Earnings today: Cellectis SA (CLLS) and Prime Medicine (PRME)
Pre-open Signals: 7 Negative, 1 Positive Indications
Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!
TGIF
October 26, 2025
A sector catalyst
Novartis NVS) has agreed to buy Avidity Biosciences (RNA) closed up Friday +$0.60 or +1.24% to $49.15 for about $12 billion.
NVS will pay Avidity shareholders $72 a share in cash, a premium of 46% to the company’s Friday closing price.
Avidity Biosciences is a biopharmaceutical company. RNA is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). These AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies.
November 7, 2025
Late session recovery, so what happened to November’s seasonality boom after yet another missed jobs’ report and so many more layers of uncertainty
I’m still maintaining to BUY the dips as a few Friday ups (16 of 40 covered) emerged
Pre-open Indication Scoring: 7 Hits and 1 Miss
RMi collects, interprets and disseminates cell and gene therapy sector (C>) fact-based news, trusted and verified intel and share pricing data to bridge the gap to an investment decision
Never leave an investor uninformed!
TGIF
October 26, 2025
A sector catalyst Novartis NVS) has agreed to buy Avidity Biosciences (RNA) closed up Friday +$0.60 or +1.24% to $49.15 for about $12 billion. NVS will pay Avidity shareholders $72 a share in cash, a premium of 46% to the company’s Friday closing price. Avidity Biosciences is a biopharmaceutical company. RNA is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). These AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies.
October 24, 2025
ADVM is up +$0.14 or +3.349% to $4.32 ADVM's lead program, Ixo-vec, is a P3 intravitreal gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Ixo-vec is designed as a single 1-time treatment to deliver continuous and stable intraocular aflibercept levels, thereby reducing the significant patient burden associated with current chronic anti-VEGF therapies, while also potentially leading to improved vision outcomes.
October 15, 2025
Who is pumping the volume thus the price, after the usual small and inching volume or no volume Challenging and questionable "aspects" state the obvious – a Ponzi Scheme! They’re BROKE filing with yet another PPM unfulfilled! What valuation model would even/ever justify a PPM pricing? Accumulated deficit to date= $103.2 M in 12 years WHO is their major shareholder – DST Capital and itsDAILY buyer, OTCQB: HRGN’s in-house fund run by its president Hong Yu, funded by Mrs. bin (Zhao) of Weston, Mass. ??? U.S. investors BEWARE, forewarned is forearmed?
3 hours 37 min ago
RMi Closing Bell: Watching
12 hours 26 min ago
RMi pre-open: Cry or
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
